Zacks Investment Research downgraded shares of SANGAMO BIOSCI (SGMO) from OUTPERFORM to NEUTRAL on December 25, 2012, with a target price of $6.60.
Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SANGAMO BIOSCI (SGMO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment